An update in treatment options for multiple myeloma in nontransplant eligible patients.

about

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

P2860

Q28076147-241FBCC5-229D-4419-9E8C-B7F2A611DF8D Q37536148-99E03DCE-C0C8-4D8F-B9AE-AE15DF31B24F

P2860

An update in treatment options for multiple myeloma in nontransplant eligible patients.

Item

http://www.wikidata.org/entity/Q38561373

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

An update in treatment options for multiple myeloma in nontransplant eligible patients.

@en

type

Item

label

An update in treatment options for multiple myeloma in nontransplant eligible patients.

@en

prefLabel

An update in treatment options for multiple myeloma in nontransplant eligible patients.

@en

P1476

An update in treatment options for multiple myeloma in nontransplant eligible patients.

@en

P2093

Annemiek Broijl

http://www.w3.org/2001/XMLSchema#string

P2860

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

P304

1945-1957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1075507

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Sonneveld

P577

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26245702

http://www.w3.org/2001/XMLSchema#string

An update in treatment options for multiple myeloma in nontransplant eligible patients.

about

P2860

P2860

An update in treatment options for multiple myeloma in nontransplant eligible patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698